

## **BRUNO WOHLSCHLEGEL**

Chief Executive Officer

### **Personal Data**

Date of Birth: 12.07.1967

Nationality: German

Place of Residence: Offenburg

In the Executive Board since: September 2023

Appointed until: 2025



### **Professional Development**

- since 09/2023: Chief Executive Officer, APONTIS PHARMA AG
- since 2022: Founder and General Manager, be executive GmbH
- 2020-2021 General Manager, Merck Serono GmbH
- 2018-2019 Senior VP Europe, Healthcare Business Merck KGaA (ad. Int.)
- 2017-2019 Regional VP Middle Europe, Healthcare Business Merck KGaA
- 2014-2017 Managing Director & General Manager, Merck s.a. Portugal
- 2013-2014 Business Unit Head Oncology, Merck Serono GmbH, Germany
- 2012-2013 Business Unit Head Neurology, Merck Serono GmbH, Germany
- 2010-2012 Head of Global Strategic Marketing Oncology, Merck KGaA
- 2007-2010 Head of Global Strategic Marketing Erbitux, Merck KGaA
- 2004-2007 Head of of Marketing Oncology, Merck Pharma GmbH, Germany
- 2002-2004 Product Manager Oncology, Aventis, Germany
- 1999-2002 Product Manager Cardiovascular & Endocrinology, Merck Pharma, Germany
- 1996-1999 Sales Representative, Merck Pharma, Germany

### **Professional Education**

- 1999–2000 Business Economics, AKAD, Stuttgart, Germany
- 1995–1996 Diploma-Thesis, Tumorbiologie Freiburg, Germany  
Targeted therapies in oncology
- 1989–1995 Diploma-Chemistry, University Freiburg, Germany  
Organic chemistry & drug development

Memberships in Statutory Domestic Supervisory Boards and in Comparable Domestic and Foreign Supervisory Bodies of Business Enterprises:

- None